Neutrophilic Asthma and Potentially Related Target Therapies.
Neutrophilic asthma is generally associated with the absence of eosinophils and activation of non-predominant type 2 immunological pathways. It involves bronchial inflammation followed by different degrees of airway remodeling. Environmental factors such as exhaust fumes, cigarette smoke, occupation-related agents, and infections have been associated with neutrophilic inflammation which activates specific cellular and molecular pathways leading to neutrophilic inflammation. This review discusses the involvement of neutrophils in asthma and potentially related target therapies. Corticosteroid resistance is the hallmark of neutrophilic asthma which increases disease severity and leads to difficult-to-control asthma. Patients with neutrophil-dominant asthma are characterized by low levels of (or absence of) Th2 cytokines. Due to the shortage of effective treatments for neutrophilic asthma newer biologics are being developed that target type 2 asthma symptoms and phenotypes. Understanding different biomarkers, inflammatory pathways and treatment strategies involved in neutrophilic asthma will help decrease adverse effects related to corticosteroid insensitivity. A better understanding of neutrophilic inflammation targets can lead to improved therapies. Further evaluation and clinical trials of emerging biologics need to be performed before bringing them into clinical practice.